U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Harpreet Singh, Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Eias Zahalka(Center for Drug Evaluation and Research), Chao Liu(Chinese PLA General Hospital), Michael H. Brave(United States Food and Drug Administration), Elektra J. Papadopoulos(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Rajesh Venugopal(United States Food and Drug Administration), Joyce Cheng(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Paul G. Kluetz(United States Food and Drug Administration), Pengfei Song(Henan University), Geoffrey Kim(United States Food and Drug Administration), Xing Wang(Chinese Academy of Sciences), Qi Liu(United States Food and Drug Administration), Yaning Wang(Yangzhou University), Jingyu Yu(Center for Drug Evaluation and Research), Amy E. McKee(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Selena Daniels(United States Food and Drug Administration)
Cited by 54
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k